STAT6 rs703817 GENE POLYMORPHISM IN PATIENTS WITH HEPATITIS B VIRUS - RELATED HEPATOCELLULAR CARCINOMA
Main Article Content
Abstract
Objectives: Determine the genotype prevalence of STAT6 rs703817 polymorphism, the relationship with some clinical and subclinical features, and the cancer risk in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Subjects and methods: A cross-sectional-related HCC patients were compared with 86 HBV-related cirrhotic patients and 195 control subjects at 108 Military Central Hospital, 103 Military Hospital, and Can Tho General Hospital from 7/2017 - 8/2020. Analysis of STAT6 rs703817 from peripheral blood samples of study subjects using the Sanger sequencing method at the Institute of Biomedicine and Pharmacy-Vietnam Military Medical University. Result: The frequency of G alleles in patients with HCC was lower (57.6%) compared to the combined frequency in the cirrhosis group and healthy individuals (69.2%), p < 0.05. The prevalence of genotype AA in patients with hepatocellular was 26.3%, higher than the corresponding rates in the cirrhosis group and healthy subjects (8.1% and 8.9%, respectively), p < 0.01. There was no association between the polymorphism of the STAT6 rs703817 and age, serum AFP levels, or certain tumor characteristics. Conclusions: STAT6 rs703817 AA genotype increases hepatocyte risk in HBsAg(+) patients, but not about serum AFP levels or other tumor features.
Article Details
Keywords
STAT6 polymorphism, Hepatocellular carcinoma.
References

2. Marrero J.A., Kulik L.M., Sirlin C.B., et al. (2018). Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases, Hepatology. 68(2): 723-750.

3. Hin Tang J.J., Hao Thng D.K., Lim J.J., et al. (2020). JAK/STAT signaling in hepatocellular carcinoma, Hepat Oncol. 7(1): HEP18.

4. Bộ Y Tế (2012). Hướng dẫn chẩn đoán và điều trị ung thư tế bào gan nguyên phát, Ban hành kèm theo Quyết định số: 5250/QĐ-BYT ngày 28 tháng 12 năm 2012 của Bộ trưởng Bộ Y tế.

5. Kamerkar S., Leng C., Zhang K., et al. (2021). 842 Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of hepatocellular carcinoma (HCC), Journal for ImmunoTherapy of Cancer. 9(Suppl 2): A883-A883.

6. Dong Z., Chen Y., Yang C., et al. (2019). STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma, Onco Targets Ther. 12: 7175-7191.
